DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
LOE - 2 Wells - 2 it's - 2 Morgan Stanley - 2 Tesla - 1 Goldman Sachs - 1 Goldman - 1 Raymond James - 1
Top related locs:
Wells Fargo China Northland EBITDA 4Q23 BLCO
Top related orgs:
UBS - 2 Bank of America - 2 Nvidia - 2 HSBC - 1 Pfizer - 1 ADC - 1 JPMorgan downgrades - 1 Verizon - 1

Search resuls for: "LOE"


5 mentions found


☆ Here are Friday's biggest analyst calls: Apple, Nvidia, AT&T, Tesla, Disney, Amazon, Microsoft & more
  + stars: | 2023-07-14 | by ( Michael Bloom | ) www.cnbc.com   time to read: +6 min
JPMorgan downgrades AT & T to neutral from overweight JPMorgan downgraded the telecommunications due to "slowing growth drivers." Wells Fargo downgrades Progressive to equal weight from overweight Wells said it has concerns about the insurance company gaining share. UBS upgrades Microsoft to buy from neutral UBS said in its upgrade of the stock that shares are too attractive to ignore. Bank of America reiterates Amazon as buy Bank of America said it's standing by its buy rating after the company's Prime Day. JPMorgan reiterates Apple as overweight JPMorgan said recent checks show that Apple has "strong market share" in a variety of markets.
Persons: LOE, Wells, it's, Tesla, Morgan Stanley, Goldman Sachs, Goldman, Raymond James, Robert Iger, Mills, Argus Organizations: HSBC, Pfizer, ADC, JPMorgan downgrades, Verizon, Mobile, Consumer, JPMorgan, Alcoa, UBS, Microsoft, Citi, Applied Materials Citi, Bank of America, Texas Roadhouse Citi, Texas, Barclays, Apple, Sands, Macau, Northland, Nvidia, Pulte, KB, Disney, CNBC, DIS, Argus, TNT, Tidewater Locations: Wells Fargo, China, Northland
☆ Here are Friday's biggest analyst calls: SoFi Technologies, AutoZone, Nvidia, Meta and more
  + stars: | 2023-06-16 | by ( Sarah Min | ) www.cnbc.com   time to read: +6 min
Bank of America downgrades SoFi Technologies to neutral from buy The downgrade follows SoFi' s recent rally. Our C$51 Price Target is 39% above the current stock price and we see close to 3:1 upside/downside skew." UBS upgrades AutoZone to buy from neutral Analyst Michael Lasser raised the price target to $2,900 from $2,800. Wells Fargo initiates Neogen Corporation at overweight and $22 price target Wells Fargo said it liked the company's improving margins. Wells Fargo initiates Bio-Rad Laboratories Inc. at overweight and $550 price target Wells said Bio-Rad's valuation is attractive at current levels.
Persons: Jefferies, John Hecht, LendingClub, Morgan Stanley, Mauricio Serna, Aritzia, Michael Lasser, Carvana, it's, Wells, Ph3, Wells Fargo, Piper Sandler, TD Cowen downgrades, LOE, Michael Bloom Organizations: . Bank of America, Technologies, Nvidia, Bank of America, UBS, West Pharmaceutical Services, Stevanato, MorphoSys, Neogen, Rad Laboratories Inc, SoFi Technologies, Health Companies Locations: EBITDA, 4Q23, BLCO
☆ Bank of America reveals the most undervalued stocks on Wall Street, including this motorcycle giant
  + stars: | 2023-02-11 | by ( Michael Bloom | ) www.cnbc.com   time to read: +6 min
CNBC Pro combed through top Bank of America research to find the most undervalued stocks on Wall Street. The firm says its base case is that the already "undervalued" stock can re-rate from current levels. In addition, Harley's management team is executing well with electric vehicle motorcycles on the horizon and burgeoning international growth opportunities. The says it sees "asymmetrical upside potential" meaning that when peers in the sector go up, KKR shares could go even higher. Remain Buy for undervalued growth and pipeline with two launches worth 5bn euros peak in 23E.
☆ Bank of America upgrades Merck, says pharma giant will outperform even as macro pressures mount
  + stars: | 2023-01-04 | by ( Sarah Min | ) www.cnbc.com   time to read: +3 min
Investors can expect further gains from Merck this year, Bank of America said. Analyst Geoff Meacham upgraded shares to buy from neutral, saying the pharmaceutical company will continue to outperform even as macro pressures mount in 2023. Merck's core business in Keytruda continued to show strong performance, and it has several strategies in place for the loss of exclusivity. Loss of exclusivity is the set amount of time a pharmaceutical company can legally develop, sell and market a treatment. Keytruda is expected to be greater than 45% of Merck's total revenue in 2025, according to the note.
☆ Fullt time Librarian and LOE (language other than English) Teacher
  + stars: | 2021-01-21 | by ( Alte Articole | ) www.civic.md   time to read: 1 min
Administratorii portalului nu poartă răspundere pentru conţinutul postărilor şi materialelor plasate de utilizatorii site-ului. Utilizaţi informaţia din acest articol pe propriul risc.
0 next >>
Total: 5